| Prev Close | 90.74 |
| Open | 90.76 |
| Day Low/High | 90.21 / 90.79 |
| 52 Wk Low/High | 72.30 / 92.39 |
| Volume | 806.10K |
| Avg Volume | 2.22M |
Novartis AG (NVS)
90.51
0.23
0.25
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 229.28B |
| EPS | 5.50 |
| P/E Ratio | 16.72 |
| Div & Yield | 1.86 (2.77%) |
Latest News
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Novartis Stock Is Poised to Rise Another 15% From Here
The stock's performance has been impressive in the past three months.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Tilray Is Now a Top-Tier Cannabis Play
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal
Pot stock partnerships are a gateway to gains for cannabis investors.
Tilray Stock Higher Ahead of First Post-Legalization Earnings Release
Tilray will have a lot to tackle this evening.
A Reckless Fed: Market Recon
It's time for the central bank to show the same level of concern for their misplaced aggression.
Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
Novartis Is Ready to Rally From a Large Base Pattern
Let's check out the latest charts and indicators for some technical guidance.
Jim Cramer: Reefer Madness
Tilray's a disruptive company for many industries.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Biotech Stocks Getting Their Due Respect
Here are two I think will bounce back before the end of the year.
Comcast Is Among 8 Stocks That Are Ready to Change Direction
These names are showing bullish or bearish reversal patterns over the past week.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Closing Bell: LIVE MARKETS BLOG
Markets closed the last day of June trading on a high note Friday.
Novartis Doesn't Appear Ready to Make Healthy Move Higher
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning
Happy Friday! These are the stories you must know ahead of the opening bell.
Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
5 Thing You Must Know Before Monday's Opening Bell
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
There Is Good and a Lot of Bad in General Electric Earnings
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
Markets Nicely Off Today's Lows
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
